

Docket No. 3842-4050

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

AUG 1 4 2003

Applicant(s):

Francis Michon, et al.

1645 Group Art Unit:

TECH CENTER 1600/2900

Serial No.:

09/853,367

Examiner:

S. Devi

Filed:

May 11, 2001

For:

IMMUNOGENIC COMPOSITIONS OF LOW MOLECULAR WEIGHT HYALURONIC ACID AND METHODS TO PREVENT, TREAT AND

DIAGNOSE INFECTIONS AND DISEASES CAUSED BY GROUP A AND

GROUP C STREPTOCOCCI

EXPRESS MAIL CERTIFICATE

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Express Mail Label No.: EV 245491849 US

Date of Deposit: August 11, 2003

I hereby certify that the following attached paper(s) and/or fee

- 1. Information Disclosure Statement (3 pages);
- 3. Copies of documents cited in Form PTO-1449 including Search Report (6 total documents);
- Check in the amount of \$180.00; and

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

(Typed or printed name of person mailing papers(s) and/or fee)

(Signature of person mailing paper(s) and/or fee)

Correspondence Address:

MORGAN & FINNEGAN, L.L.P. 345 Park Avenue New York, NY 10154-0053 (212) 758-4800 Telephone

(212) 751-6849 Facsimile

08-12-03

Docket No. 3842-4050

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Francis Michon, et al.

Group Art Unit:

1645

Serial No.:

09/853,367

Examiner:

S. Devi

Filed:

May 11, 2001

For:

IMMUNOGENIC COMPOSITIONS OF LOW MOLECULAR WEIGHT HYALURONIC ACID AND METHODS TO PREVENT, TREAT AND

DIAGNOSE INFECTIONS AND DISEASES CAUSED BY GROUP A


AND GROUP C STREPTOCOCCI

INFORMATION DISCLOSURE STATEMENT

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97 Sir: and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

respectfully requested to fully consider the items and to a respectfully requested to fully consider the items and to a respectfully requested to fully consider the items and to a respectfully requested to fully consider the items and to a respectfully requested to fully consider the items and to a respectfully requested to fully consider the items and to a respectfully requested to fully consider the items and to a respectfully requested to fully consider the items and to a respectfully requested to fully consider the items and to a respectfully requested to fully consider the items and to a respectfully requested to fully consider the items and to a respectfully requested to fully consider the items and to a respectfully requested to fully consider the items and to a respectfully requested to fully consider the items and to a respectfully requested to a respectfully requested to a respectfully requested to a respectfully requested to a respectfully representation of the following items listed on the enclosed copy of Form PTO-1449 that items are a respectfully representation of the r				
1.	\boxtimes	For each of the following items listed on the enclose not in the English language, an English language tr thereof or a concise explanation of the relevance of t	anslation of that item or a portion hat item is enclosed:	
		JP 09 012600 A	ed copy of Form PTO-1449 that is	
2.		not in the English language, a continuous incorporated in the specification of the above-identi	ns listed on the enclosed copy of results of the statement was previously cited by or information Disclosure Disclosur	
3.		enclosed with this information a submitted to the Patent and Trademark Office in a		
			s Information Disclosure Statement	
4.		No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with: 37 C.F.R. §1.97(b)(1), within three months of the filing date of a national compliance with them a CPA: or		
		application other than a CPA; or		
		08/13/2003 KBETEHA1 00000026 09853367	Express Mail No. EV 245491849 US	



·	37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or
	37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the
	37 C.F.R. §1.97(b)(4) before the mailing date of a first office action after the filing of an RCE under §1.114.
5.	No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.
6.	A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action):
	A check in the amount of \$180.00 is enclosed in payment of the fee.
	Charge the fee to Deposit Account No. 13-4500, Order No A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
7.	A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue
	fee, and is accompanied by: fee, and is accompanied by: 1.97(e) set forth in paragraph 9
	 a. one of the continuous 1 below; and b. the fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11
1	b. the fee due under 37 C.F.R. §1.17(p) which is problem.
8.	A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:
	a. 37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);

b. 37 C.F.R. §1.313(c)(2) or §1.313(c)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h).	
C.F.R. §1.17(n). c. The fees due under 37 C.F.R. §§1.17(h) and 1.17(p) are paid as set forth in	
paragraph 11 below.	
paragraph 11 below. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a Statement was first cited in a communication from a prior to the filing of this counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.	
I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to was known to any individual designated in §1.56(c) more than three months prior to	
- a 1 Deport Ollillumound	
the filing of this information Passa. This document is accompanied by \(\subseteq \ a \) Search Report \(\subseteq \) Communication which was cited in a corresponding \(\subseteq \) PCT or \(\subseteq \) Foreign counterpart application	
cited in a corresponding 100 100 100 100 100 100 100 100 100 10	
11. A check in the amount of \$100.00 and 1.17(n).	
11. A check in the C.F.R. §§1.17(h) and 1.17(p). C.F.R. §§1.17(h) and 1.17(p) to Deposit Account No. Charge the fees due under 37 C.F.R. §§1.17(h) and 1.17(p) to Deposit Account No. 13-4500, Order No A DUPLICATE COPY OF THIS SHEET THIS	
13-4500, Order No	
ATTACHED.	;
ATTACHED. The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500, Order No. 3842-4050. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.	?
Respectfully Submitted,	
TOPICAN & FINNEGAN, L.L.P.	
Sulz Mitter	
Dated: August 11, 2003 By: Evelyn M. Kwon	
Registration No. 54,246	
Correspondence Address: MORGAN & FINNEGAN, L.L.P. 345 Park Avenue New York, NY 10154-0053	
(212) 758-4800 Telephone	
(212) 751-6849 Facsimile	
(212) 751 00 11	C





FORM PTO-1449

Attorney Docket: Serial No.: 09/853,367	
3842-4050 09/853,367	
Applicant:	
n :- Michon et al	
1645	A COLUMN CO.

INFORMATION DISCLOSURE CITATION May 11, 2001 U.S. PATENT DOCUMENTS Filing Date Sub-Class Publication Class Patent Examiner Name Apr. 21, Date Number Initial Milan Blake, et al. Feb. 2. 1999 US 5,866,135 AUG 1 4 2003 TECH CENTER 1600/2900 FOREIGN PATENT DOCUMENTS Translation Publication **Sub-Class** Class Patent Examiner Country Yes No Date Number Initial PCT Dec. 9, 1999 WO99/62546 ☐ Yes ☐ No Jan. 14, Japan Yes No JP 09 012600A 1997 Yes No Yes No ☐ Yes ☐ No Yes No Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, etc.) O'Hagan, DT, Journal of Pharmacy and Pharmacology, "Recent Advances In Vaccine Adjuvants For Systemic And Mucosal Administration" Vol. 49, No. 1, January 1998, pp 1-10. Humphrey, JH, European Journal of Immunology, "Tolerogenic Or Immunogenic Activity Of Hapten Conjugated Polysaccharides Correlated With Cellular Localization" Vol. 11, No. 3, 1981, pp 212-220. Date Considered Examiner Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. EXAMINER:

Express Mail No. EV 245491849 US

Include copy of this form with next communication to Applicant.